A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention

Exclusion Criteria

• •Women who are pregnant or breast feeding.
• •Planned PCI with multi-vessel stenting.
• •Planned PCI with additional revascularization procedures staged at different days during the study period.
• •Planned PCI other than stenting (e.g., atherectomy, PTCA without stenting, etc).
• •Planned PCI of any bypass graft.
• •History of CABG surgery.
• •Planned cardiac or major non-cardiac surgery within the study period.
• •Disabling stroke in the past 6 months.
• •History of chronic viral hepatitis or other chronic hepatic disorders.
• •History of Gilbert's syndrome or elevated bilirubin concentrations at screening.
• •History of increased liver function tests (ALT, AST) due to acute or chronic liver conditions, above the upper limit of normal at screening or in the past 6 months.
• •Renal impairment with serum creatinine \>2.0 mg/dl (177umol/L) at Screening, or history of kidney transplant, or a history of contrast nephropathy.
• •Current inadequately controlled hypertension (blood pressure \>160 mmHg systolic and/or \>100 mmHg diastolic) on a stable dose of antihypertensive medication.
• •Current poorly controlled diabetes mellitus, defined as HbA1c \>10% at Screening.
• •History of severe heart failure defined as NYHA class III or IV or those with known severe LV dysfunction (EF\<30%) regardless of symptomatic status.
• •History of malignancy within the past 5 years, other than non-melanoma skin cancer.
• •Current life-threatening condition other than vascular disease that may prevent a subject from completing the study.
• •Alcohol or drug abuse within the past 6 months.